Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Essential thrombocythemia | D013920 | — | D47.3 | — | — | 3 | — | — | 3 |
Thrombocytosis | D013922 | — | D75.83 | — | — | 3 | — | — | 3 |
Polycythemia vera | D011087 | — | D45 | — | — | 1 | — | — | 1 |
Primary myelofibrosis | D055728 | — | D47.4 | — | — | 1 | — | — | 1 |
Polycythemia | D011086 | EFO_0005804 | D75.1 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Drug common name | Bomedemstat |
INN | bomedemstat |
Description | Bomedmestat (USAN; IUPAC name N-[(2S)-5-[[(1R,2S)-2-(4-fluorophenyl)cyclopropyl]amino]-1-(4-methylpiperazin-1-yl)-1-oxopentan-2-yl]-4-(triazol-1-yl)benzamide) is an investigational drug under development by Imago BioSciences for the treatment of myeloproliferative neoplasms including essential thrombocythemia, polycythemia vera and myelofibrosis.
|
Classification | Small molecule |
Drug class | enzyme inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CN1CCN(C(=O)[C@H](CCCN[C@@H]2C[C@H]2c2ccc(F)cc2)NC(=O)c2ccc(-n3ccnn3)cc2)CC1 |
PDB | — |
CAS-ID | 1990504-34-1 |
RxCUI | — |
ChEMBL ID | CHEMBL4297289 |
ChEBI ID | — |
PubChem CID | 122460381 |
DrugBank | DB15126 |
UNII ID | Y2T4ALDEAT (ChemIDplus, GSRS) |